On the filings, Salesforce (CRM) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it BUY.
Best-in-class CRM SaaS growing ~19% with 84% gross margins and strong cash flow, but its multiple on razor-thin GAAP profit caps near-term upside.
Quality SaaS compounder at a value multiple: its multiple, ~10% FCF yield, EPS +23%, RPO +14% — the de-rating is the opportunity.
| Metric | HUBS | CRM |
|---|---|---|
| Fundamentals score | 70 | 80 |
| Revenue growth (YoY) | +19.2% | +9.6% |
| Net income growth (YoY) | +892.0% | +20.3% |
| Net margin | 1.5% | 18.0% |
| Return on equity | 2.2% | 12.6% |
| ROIC (est.) | 0.3% | 8.9% |
| Liabilities / Equity | 0.87 | 0.90 |
| Piotroski F-score | 5 / 9 | 7 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:45 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 7:22 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.